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Abstract
Wheat, once thought to be a critical ingredient in a healthy diet, has become a major threat, according to public
opinion. The term non-celiac gluten sensitivity has been widely adopted to describe a clinical entity characterized
by symptoms induced by gluten without the diagnostic criteria found in other gluten-related disorders. However, it
has not been shown that gluten per se is involved, and it can be debated if the condition is a disease. Nevertheless,
a large number of individuals go gluten-free, avoiding wheat, rye and barley, even without a defined medical cause.
In a study in BMC Medicine, Volta and colleagues from Italy report on a large, multicenter attempt to enumerate the
prevalence of non-celiac gluten sensitivity in secondary gastroenterology care. They found that approximately 3%
of their more than 12,000 patients fulfilled their criteria for non-celiac gluten sensitivity. However, we are still
challenged with finding stricter clinical criteria for the condition, developing a usable clinical approach for gluten
challenge in these individuals, and understanding the pathogenesis of the condition.
Please see related article http://www.biomedcentral.com/1741-7015/12/85.
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Background
In the Western world, consumption of wheat has in-
creased over the last half-century [1], as have the standard
of living and life expectancy. Wheat is now more desirable
than rice in large populations in China and India [2].
However, we now see a trend in Europe, Australia, New
Zealand and the US to avoid dietary wheat. The numbers
are uncertain, but prevalence up to 6% has been sug-
gested. This trend is so pronounced that the consump-
tion of wheat has declined [1], and it raises important
questions. Are disease mechanisms involved? Is there
any health benefit or risk from avoiding gluten? Is the
trend solely due to public pressure? Could all those con-
sumers be mistaken? Why adopt a strict, restrictive diet
without a well-defined medical reason?
‘Gluten’ as a term is complicated. A gluten-free diet
(GFD) is one without wheat, rye and barley. Gluten also
refers to the glue-ish mass remaining after washing wheat
flour with water. In addition, gluten describes the storage
proteins found in cereals, those proteins that have well-
known baking properties. The term ‘gluten-related dis-
orders’ is also complicated [3,4]. At least three clinical en-
tities are recognized: celiac disease (CD), wheat allergy,
and non-celiac gluten sensitivity (NCGS). CD is a gluten-
induced inflammatory disorder of the small intestinal mu-
cosa, with typical serology comprising immunoglobulin
(Ig) A antibodies to the enzyme tissue transglutaminase or
deamidated gliadin peptides. Wheat allergy is an acute
anaphylactic condition, with the presence of IgE to gluten.
Lastly, NCGS is characterized by clinical signs induced by
gluten, but without the same diagnostic criteria. Thus,
NCGS is so far defined only by clinical terms - with all the
problems we often see when clinicians lack strict criteria.
The link to and comparison with irritable bowel syndrome
is obvious. Irritable bowel is also diagnosed clinically, and
can be treated by food restriction [5], but whether these
entities really overlap remains to be seen.
Non-celiac gluten sensitivity versus celiac disease
In a study published in BMC Medicine, Volta and col-
leagues report a multicenter, prospective study on pre-
valence of NCGS [6]. Thirty-seven specialist centers
participated, all with expertise in gluten-related disor-
ders. In Italy, such centers are accredited by the govern-
ment and are responsible for reimbursement for GFD.
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The study evaluated 12,255 patients. The authors found
486 patients (3.19%) with NCGS, with a mean age 38
years, and a female to male ratio of 5.4:1. At the same
time, they identified CD in 340 patients (2.77%). In the
NCGS population, half of them had signs compatible
with irritable bowel syndrome and received that diag-
nosis as well. Other frequent findings were allergies,
autoimmune diseases and a close relative with CD. La-
boratory tests showed low levels of ferritin, folic acid
and vitamin D, but only in a minority. They found in-
creased levels of IgG to gluten, but only in 25% of their
patients. Disease controls were not reported. The authors
should be congratulated for their efforts.
Although well conducted, there are some comments to
be made. Firstly, the cut-off for diagnosis of NCGS in the
study was not clear. The authors used a 60-item doctor-
answered questionnaire with ‘yes/no’ items. There was no
requirement for a given number of positive answers for a
diagnosis. It appears that the diagnosis of NCGS was done
‘clinically’. Secondly, it is unclear if the participating clini-
cians in fact approved the patient’s use of their GFD.
Thirdly, the study did not include a systematic placebo-
controlled food challenge. This is often considered the
gold standard for food intolerance, but is clinically
problematic [7].
The study of Volta et al. showed NCGS in approxi-
mately 3% of referred patients. How this relates to the
general population is unclear. Other reports have shown
wide variations in prevalence. A study from a referral US
center found NCGS in 6% of patients [4]. A US-based
population survey study found a low prevalence of NCGS
[8], but the survey was not designed to detect NCGS. A
UK-based population study showed that 13% considered
themselves as gluten-sensitive, and 3.7% consumed a GFD
(most of them without a CD diagnosis) [9]. In New
Zealand, 5% of children are on a GFD [10]. Thus, it
is reasonable to accept that a noteworthy proportion
of the Western population is on a GFD.
Are there reasons to worry about people having a
GFD? We have no estimates on any health benefits of a
GFD in the NCGS population, in contrast to the known
benefits in the CD population. We do not yet have any
proof that a GFD has a negative health effect on the
NCGS population, whereas there is some evidence that
it may in CD, because treated patients show signs of nu-
tritional deficiency [11]. Thus, the short answer is that
in the case of NCGS a GFD is neither medically needed
nor detrimental. However, NCGS has many similar as-
pects to irritable bowel syndrome, a condition that has a
severe impact on a patient’s quality of life and represents
a very significant financial burden on all Western health
care system. It is therefore necessary to developing a us-
able clinical approach for gluten challenge in individuals
with NCGS.
Well, then, how to investigate? It depends on whether
the patient is still on a gluten-containing diet or a GFD.
The objective signs of CD, with serology and mucosal
inflammation, normalize when a patient with CD com-
mences a GFD. Thus, serological testing with anti-tissue
transglutaminase IgA should be done before any clinician
advocates a GFD. If the patient is already gluten-free, an-
other approach should be taken. In fact, CD is not fre-
quent in the NCGS population, and a clinical response to
gluten withdrawal is not proof that the patient has CD
[12-14]. Genetic analysis for human leukocyte antigens
DQ2 and DQ8 is useful, because it is highly unlikely that
CD is the causal disease in the absence of these genetic
variants [15,16]. Further investigation of possible CD in-
volves gluten challenge of two to six weeks’ length or
more where the aim is to provide objective signs of CD
[17,18].
Gluten challenge or withdrawal to prove or disprove
NCGS is complicated. A blinded challenge approach
would be ideal, but the standard test with flour in cap-
sules is problematic and rarely used [7]. A good placebo
food preparation is essential, and has been developed in
Australia [19,20]. Further understanding of NCGS will
require that other groups also introduce blinded, placebo-
controlled challenge protocols. It has been questioned if
NCGS actually exist, or if it is caused by sensitivity to fer-
mentable carbohydrates that are abundant in gluten-
containing cereals [20]. To further complicate the matter,
non-gluten proteins have been proposed to be important
[21], but for the wheat-sensitive patient, this does not
really matter. Moreover, the use of a wide array of symp-
tom evaluations and lack of a standardized symptom scor-
ing form represent major obstacles to further progress.
Conclusions
The use of a GFD without a well-defined medical reason
has reached considerable proportions in many Western
societies. The clinical entity NCGS resembles, and may
well be a part of, irritable bowel syndrome. The diagno-
sis of both conditions is based on clinical work-up; ob-
jective biomarkers are not available and may be difficult
to develop. NCGS may be caused by improper immune
responses, intolerance to poorly digestible and ferment-
able substances in the wheat, or a combination of these.
NCGS is a burden for the affected individuals and for
the healthcare system trying to provide proper help for
them. Future research should address whether gluten
really is involved, and if a manageable, clinically accept-
able, placebo-controlled investigation procedure can be
developed. We should aim provide relief for those who
really benefit from dietary restriction, without over-
treating those who would benefit from more tempo-
rary interventions.
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